Xagrid, known generically as anagrelide, is a pharmaceutical medication primarily used in the treatment of essential thrombocythemia (ET), a rare chronic blood disorder characterized by the overproduction of platelets by the bone marrow. This condition can lead to complications such as blood clots, which can cause serious health issues like strokes or heart attacks. Xagrid works by inhibiting the production of platelets, thereby reducing their numbers in the bloodstream and minimizing the risk of clotting. It is classified as a platelet-reducing agent and is often prescribed when first-line therapies have not been effective or are not suitable for the patient. As with any medication, the use of Xagrid should be closely monitored by a healthcare provider to manage any potential side effects and to ensure its efficacy in the treatment regimen.